دورية أكاديمية
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
| العنوان: | Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. |
|---|---|
| المؤلفون: | Tanguy-Schmidt, Aline, Rousselot, Philippe, Chalandon, Yves, Cayuela, Jean-Michel, Hayette, Sandrine, Vekemans, Marie-Christiane, Escoffre, Martine, Huguet, Françoise, Réa, Delphine, Delannoy, André, Cahn, Jean-Yves, Vernant, Jean-Paul, Ifrah, Norbert, Dombret, Hervé, Thomas, Xavier |
| المساهمون: | Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses CH Versailles (CeRéMAIA - Hôpital André Mignot), Centre Hospitalier de Versailles André Mignot (CHV), Laboratoire central d'hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Biologie Moléculaire, Hospices Civils de Lyon (HCL), Service Hématologie - IUCT-Oncopole CHU Toulouse, Pôle Biologie CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de Jolimont, Haine-Saint-Paul and Cliniques Universitaires St Luc, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie clinique Avicenne, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne AP-HP, Lymphocyte et cancer, IFR105-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot CHU - HCL |
| المصدر: | ISSN: 1083-8791. |
| بيانات النشر: | HAL CCSD Elsevier |
| سنة النشر: | 2013 |
| المجموعة: | HAL Lyon 1 (University Claude Bernard Lyon 1) |
| مصطلحات موضوعية: | MESH: Adolescent, MESH: Adult, MESH: Transplantation, Autologous, Homologous, MESH: Age Factors, MESH: Unrelated Donors, MESH: Antineoplastic Agents, MESH: Benzamides, MESH: Disease-Free Survival, MESH: Female, MESH: Follow-Up Studies, MESH: Hematopoietic Stem Cell Transplantation, MESH: Male, MESH: Humans, MESH: Middle Aged, MESH: Philadelphia Chromosome, MESH: Piperazines, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH: Pyrimidines, MESH: Survival Rate, MESH: Time Factors, [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/22960387; hal-00849684; https://hal.science/hal-00849684Test; PUBMED: 22960387 |
| DOI: | 10.1016/j.bbmt.2012.08.021 |
| الإتاحة: | https://doi.org/10.1016/j.bbmt.2012.08.021Test https://hal.science/hal-00849684Test |
| رقم الانضمام: | edsbas.3E928362 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.bbmt.2012.08.021 |
|---|